PolyMedix
Stage
Asset Sale | AssetsPurchasedAbout PolyMedix
PolyMedix is a clinical stage biotechnology company developing small-molecule drugs designed to mimic the activity of host defense proteins (HDPs) for the treatment of infectious diseases and innate immunity disorders. PolyMedix's compounds are designed to imitate the mechanism of action of HDPs, which contribute to natural human immunity. In contrast to existing antibiotics, PolyMedix's brilacidin, was designed to exploit a method of bacterial cell killing, via biophysical membrane attack, against which bacteria have not shown development of resistance in multiple preclinical studies. Brilacidin showed efficacy similar to an active control, and was safely administered in a Phase 2 clinical trial in patients with ABSSSI caused by Staphylococcus aureus bacteria (including methicillin-resistant Staphylococcus aureus (MRSA)). PolyMedix has plans to initiate a Phase 2B dose optimization study with brilacidin in ABSSSI patients and also to develop brilacidin as a topical treatment for radiation and chemotherapy-induced cancer oral mucositis, a common and often debilitating complication of cancer treatments.
PolyMedix Headquarter Location
170 N Radnor-Chester Road Suite 300
Wayne, Pennsylvania, 19087,
United States
484-598-2370
Expert Collections containing PolyMedix
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
PolyMedix is included in 1 Expert Collection, including Cancer.
Cancer
3,605 items
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
PolyMedix Patents
PolyMedix has filed 7 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
6/21/2012 | 8/13/2013 | G protein coupled receptors, Clusters of differentiation, Angiology, Transcription factors, Proteins | Grant |
Application Date | 6/21/2012 |
|---|---|
Grant Date | 8/13/2013 |
Title | |
Related Topics | G protein coupled receptors, Clusters of differentiation, Angiology, Transcription factors, Proteins |
Status | Grant |
Latest PolyMedix News
Oct 21, 2013
Less than two months after Beverly, Mass.-based Cellceutix Inc. snapped up PolyMedix Inc., a bankrupt biotech for $2.1 million in cash and 1.4 million shares of its stock, the company is saying it is on track for additional growth. With the acquisition of the Radnor, Pa. bankrupt biotech, Cellceutix (OTC: CTIX) disclosed today that it has doubled its initial pipeline and has prepared the company for the initiation of five Phase 2 clinical trials in 2014 including the Phase 2/3 trial of Pruri
Where is PolyMedix's headquarters?
PolyMedix's headquarters is located at 170 N Radnor-Chester Road, Wayne.
What is PolyMedix's latest funding round?
PolyMedix's latest funding round is Asset Sale.
Who are the investors of PolyMedix?
Investors of PolyMedix include Cellceutix.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.